8-K: OrthoPediatrics Corp. Reports Strong Q1 2025 Results, Raises Full Year Revenue Guidance

OrthoPediatrics Corp. announced a 17% increase in first quarter 2025 revenue and raised its full year revenue guidance.

Summary

• OrthoPediatrics Corp. reported its financial results for the first quarter ended March 31, 2025.
• Total revenue for Q1 2025 was $52.4 million, a 17% increase compared to $44.7 million in Q1 2024.
• Domestic revenue increased by 19% and international revenue increased by 11%.
• Worldwide Trauma & Deformity revenue grew by 14%, and Scoliosis revenue increased by 34%.
• The company achieved an adjusted EBITDA of ($0.4) million, compared to ($1.1) million in the first quarter of 2024.
• First quarter 2025 free cash flow usage was reduced by 35% compared to the prior year, with the first full quarter of positive free cash flow anticipated in Q4 2025.
• The company launched the VerteGlide System for Early Onset Scoliosis (EOS), marking its 80th system brought to market.
• Full year 2025 revenue guidance was increased to $236.0 million to $242.0 million, representing growth of 15% to 18% compared to the prior year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, improved EBITDA, and increased revenue guidance, but tempered by the net loss and increased operating expenses.

Positives

• The company helped a record of nearly 39,000 children in the first quarter of 2025.
• Revenue growth was strong, with a 17% increase year-over-year.
• Domestic revenue growth was particularly strong at 19%.
• Scoliosis revenue experienced substantial growth of 34%.
• Adjusted EBITDA improved compared to the previous year.
• Free cash flow usage decreased significantly.
• The company launched a new product, the VerteGlide System.
• Revenue guidance for the full year 2025 was increased.

Negatives

• The company reported a net loss of $10.7 million for the first quarter of 2025, compared to a net loss of $7.8 million for the same period last year.
• Sports Medicine/Other revenue decreased by 25% in the first quarter of 2025.
• Total operating expenses increased by 18% in the first quarter of 2025.

Risks

• The press release mentions risks related to widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and their potential impact on product demand.
• The company's Annual Report on Form 10-K filed with the SEC on March 5, 2025, contains a section on 'Risk Factors' that could cause actual results to differ materially from forward-looking statements.

Future Outlook

The company increased its full year 2025 revenue guidance to $236.0 million to $242.0 million, representing growth of 15% to 18% over 2024 revenue, and reiterated annual set deployment to be $15.0 million and reiterated $15.0 million to $17.0 million of adjusted EBITDA for the full year of 2025.

Management Comments

• David Bailey, President & CEO of OrthoPediatrics, stated that the company delivered another strong quarterly performance from both a revenue and profitability perspective.
• He also mentioned that the company continues to progress the scaling of OPSB, take share across its surgical business by leveraging prior set deployment, and successfully launch innovative products.
• He believes the company is well positioned for the rest of 2025 and the years to follow.

Industry Context

OrthoPediatrics operates in the pediatric orthopedics market, which is a specialized segment of the broader orthopedics industry; the company's focus on this niche allows it to develop tailored products and solutions for children with orthopedic conditions.

Comparison to Industry Standards

• While direct comparisons to competitors are not provided in this document, the company's growth rates in specific product categories like scoliosis (34%) can be benchmarked against the growth rates of other companies in the orthopedics or medical device industry.
• Companies like Stryker, Johnson & Johnson (DePuy Synthes), and Medtronic have orthopedic divisions, but they do not focus exclusively on pediatrics, making a direct comparison challenging.
• However, investors can compare OrthoPediatrics' revenue growth and profitability metrics against these larger players to assess its relative performance within the broader industry.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and improved EBITDA.
• Employees may benefit from the company's growth and expansion.
• Customers (healthcare providers) will have access to new products like the VerteGlide System.
• The company's performance could strengthen its relationships with suppliers and creditors.

Next Steps

• The company will host a conference call on May 7, 2025, to discuss the results.

Key Dates

Keywords

OrthoPediatrics, pediatric orthopedics, revenue, EBITDA, scoliosis, trauma, deformity, financial results, guidance